Alternative medicines include: Sertraline (optimum alternative as similar indications, low interaction propensity, good tolerability, generic, NICE approved)

Slides:

Advertisements

Similar presentations

Obsessive-compulsive disorder

Advertisements

Bipolar disorder July Why implement NICE guidance? NICE guidelines are based on the best available evidence The Department of Health asks NHS organisations.

Atrial Fibrillation Cardiovascular ISCEE 26th October 2010.

COMMUNITY PHARMACY WORKBOOK PUBLIC HEALTH DORSET

Pharmacologic Treatments. 2 Cognitive Behavioural Therapy (CBT) Psychosocial Interventions.

How often should they be evaluated and scanned, and how often should they have dermatologic follow-up and EKGs? How should patients responding to BRAF.

GENERALIZED ANXIETY DISORDER IN PRIMARY CARE Curley Bonds, MD Medical Director Didi Hirsch Mental Health Services Professor & Chair Charles R. Drew University.

Key dosing points: Begin a bowel regimen when opioid therapy is initiated (senna + docusate). For CHRONIC pain, use a scheduled medication regimen. ( ex:

The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure

2007. Statistics  2-4 new cases per 100,000/year  1 in 200 people will have an episode of hypomania  Peak age of onset yrs  May have had a previous.

Depression Ibrahim Sales, Pharm.D. Associate Professor of Clinical Pharmacy King Saud University

National Institute for Health and Clinical Excellence (NICE) Clinical Guideline on Depression & Anxiety  We understand how much of GP’s time is spent.

Pharmacological Treatment of Hypertension Update 2012.

Clinical Knowledge Summaries CKS Heart failure - chronic Primary care management of end stage chronic heart failure. Educational slides based on the CKS.

Clinical Knowledge Summaries (CKS) Depression

SSRIs & Antidepressants

Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.

Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)

Depression in Adolescents and Young Adults: current best practice David Hartman Psychiatrist Child, Adolescent and Young Adult Service Institute of Mental.

Basics of outpatient depression management Chris Zamani MD.

Strategies to Switch Antidepressants Brittany Parmentier, PharmD PGY2 Behavioral Care Resident Butler University/Community Health Network This speaker.

RELATIVE TOXICITY OF CITALOPRAM AND OTHER SSRIs IN OVERDOSE GK Isbister 1,2, IM Whyte 1,2, AH Dawson 1,2 1 Department of Clinical Toxicology, Newcastle.

Long QT and TdP Morning Report Elias Hanna, LSU Cardiology.

Depressive Illness and Antidepressants

Antidepressants and Suicide Risk in Children and Adolescents: Weighing the Evidence Jill A. Morris, PA-S.

Implementing NICE guidance 2011 NICE clinical guideline 113 Generalised anxiety disorder in adults.

1 QTc and Quinolones: recent regulatory actions Joyce Korvick M.D., M.P.H. Office of Drug Evaluation IV Division of Special Pathogens FDA.

Special patient groups Module 5. Introduction Worldwide, the majority of people in substitute treatment are men between Even they do not form a.

1 A review of the safety of Moxifloxacin Hydrochloride Leonard Sacks MD Medical officer/DSPIDP.

Impact of Multidisciplinary Team Care on Older People with Polypharmacy Liang-Kung Chen Center for Geriatrics and Gerontology Taipei Veterans General Hospital.

Review Update: QT Prolongation with Citalopram and Escitalopram Pediatric Advisory Committee Meeting November 16, 2006 Prepared by M. Lisa Jones, MD Division.

Using Medical Records to Supplement a Claims-Based Comparative Effectiveness Analysis of Antidepressant Treatment Thomas W. Croghan, Dominick Esposito,

Case study Which antidepressant Dr. Matthew Miller.

HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.

East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast NSAIDS – Efficacy and Safety Expert speaker.

Addressing Tobacco Use in Mental Health Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester.

Addressing Tobacco Use in Medical Settings Pharmacotherapy Materials Prepared By: Center for a Tobacco-Free Finger Lakes University of Rochester School.

Department of Pharmacy, Ditmanson Medical Foundation Chia-Yi Christian Hospital Suspect Moxifloxacin Induced Torsades de Pointes: A case report Ya-Wen.

NICE guidance Generalised Anxiety Disorder Alex Hill.

Medicines that interact with alcohol See “Guidance on the administration of medicines to inpatients believed to have consumed alcohol ”

Management of Depression in Adults Jon van Niekerk.

Treating generalised anxiety disorder in primary care – an example of a treatment pathway Step 3: review and consideration of alternative treatments Step.

Depression and Aging Aging Q 3 William P. Moran, MD, MS Medical University of South Carolina October 31, 2012.

Efficiently dealing with new FDA information on drug safety Warnings, Shortages, Withdrawals – Oh My! Efficiently dealing with new FDA information on drug.

Tachykardie / bradykardie

Pharmacological management of delirium

ECG interpretation Amarpal Bains.

COMMUNITY PHARMACY WORKBOOK PUBLIC HEALTH DORSET

By dr.safeyya alchalabi

Psychiatric Treatment

Obsessive Compulsive Disorder (OCD) Abdulaziz S. Alsultan

Mini-collaborative Medicines management/dementia care

Step 1: recognition and diagnosis Step 2: treatment in primary care

Opioids Aware A resource for patients and HCPs to support prescribing of opioid medicines for pain Sue Mulvenna CDAO NHSE S SW March 2016.

3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.

What Are The Treatment For Anxiety And Panic Disorder.

Medication for Mummies

Trimipramine – Summary of West Suffolk CCG and PrescQIPP Guidance

Clinical Intake Assessment

PHARMACOTHERAPY - I PHCY 310

WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in

Citalopram and Escitalopram

Assessment and Management of Non-Sleep Symptoms: Using SSRIs (Node 3)

1st Line Medication Lorazepam 0.5 mg p.o/i.m

Relapses or deteriorates

Proposed ways of informing GPs about current services Dr Louise Paterson 18th January 2019.

COMMUNITY PHARMACY WORKBOOK 2019 PUBLIC HEALTH DORSET

Pharmacological Treatment of Hypertension Update 2012

Dr James Ovens Consultant Psychiatrist Tandridge CMHRS

Implications for safe medication prescribing in older adults

Presentation transcript:

Alternative medicines include: Sertraline (optimum alternative as similar indications, low interaction propensity, good tolerability, generic, NICE approved) Fluoxetine (beware of P450 interactions) Mirtazapine (depression indication only) New dose recommendations Citalopram max dose 40mg/day in adults and 20mg/day in the elderly and people with reduced hepatic function. Escitalopram max dose in elderly 10mg/day, no other dose changes. Pre-treatment (or current patients where not already checked): correct any electrolyte disturbances & undertake ECG for those with cardiac disease. Escitalopram remains non-formulary (except for use by tertiary OCD/BDD Services). Switch to different SSRI or antidepressant Other therapies considered Elderly or other risk factors above recommended dose Reduce dose stepwise. Monitor for 3 months If all other options exhausted consider maintaining previously effective dose [document unlicensed dose and rationale in notes; evidence of informed consent from service user with capacity]. Reduce and monitor any risk factors. Monitor with regular ECG (e.g. initially, 6-monthly and after any medicine or dose changes) and tell service user to report any abnormal heart rate or rhythm. If significant QT prolongation detected, must seek specialist advice and/or switch Adult above recommended dose Reduce dose stepwise. Monitor for 3 months Relapses or deterioratesRemains stable If es/citalopram dose currently above new recommendations: Discuss with service user/patient. Consider continued need for es/citalopram and alternative therapies. Consider switching if also taking any other medicines likely to cause QTc prolongation. (NB es/citalopram have few interactions and so has been a drug of choice where interactions are likely). Known to need above new MHRA recommended doses (elderly and reduced hepatic function) e.g. for OCD, PTSD Citalopram & Escitalopram maximum dose (MHRA Dec 2011) There is no comparative data available on QTc prolongation for other antidepressants/doses. There is no single switch method: Depending on es/citalopram dose, urgency, tolerability and other medicines then “drop, stop and switch” is safest. Abrupt switching is not recommended. If in doubt, consult medicines helpline (see below). If switching be aware of serotonin syndrome and es/citalopram discontinuation symptoms. Further advice: SWLStG Medicines Information on or contact your Mental Health Team 8/3/13 (Thanks to Prof S Bazire) Consider risk:benefit with service user. Switch if possible If under 18 refer to CAMHS (unlicensed use). Citalopram & escitalopram may cause a dose-dependent QTc prolongation: Contraindicated with known QTc prolongation, congenital long QT syndrome or taking other QTc-prolonging medicines e.g. antipsychotics, quinolones, macrolides & antiarrhythmics. Caution with higher risk of developing Torsades de Pointes (e.g. in heart failure, bradyarrythmia, hypokalaemia or hypomagnesemia). References see (search ‘escitalopram high dose’): Lundbeck communication and MHRA advicewww.nelm.nhs.ukLundbeck communication Other SSRIs: Check ECG if prescribing above BNF doses.